This is an international site for Glivec® (imatinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.
U.S. ResidentsLearn more about how the GLIVEC International Patient Assistance Program (GIPAP) can enhance patient access to GLIVEC. GIPAP has been expanded to 80 countries and has reached more than 27,000 patients.
Learn more about the risk
of recurrence
GLIVEC and GIST |
Glivec and Ph+ CML |
Glivec and Additional Indications |
For Your Patients |
Library and Tools |
